EXACT Sciences (EXAS) PT Set at $67.00 by Bank of America

EXACT Sciences (NASDAQ:EXAS) has been assigned a $67.00 target price by analysts at Bank of America in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the medical research company’s stock. Bank of America’s target price indicates a potential upside of 27.69% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the company. Leerink Swann reiterated an “outperform” rating and issued a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Robert W. Baird cut EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective on the stock. in a report on Monday, November 13th. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price objective (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Jefferies Group lifted their price objective on EXACT Sciences to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, BidaskClub cut EXACT Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $50.58.

EXACT Sciences (NASDAQ:EXAS) traded up $2.57 during mid-day trading on Monday, reaching $52.47. The company had a trading volume of 5,028,200 shares, compared to its average volume of 3,257,083. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. EXACT Sciences has a 12 month low of $16.95 and a 12 month high of $63.60. The firm has a market cap of $6,220.00, a PE ratio of -45.63 and a beta of 0.68.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same period in the previous year, the firm posted ($0.36) EPS. EXACT Sciences’s revenue was up 158.4% compared to the same quarter last year. equities research analysts anticipate that EXACT Sciences will post -1.1 earnings per share for the current fiscal year.

In other news, SVP D Scott Coward sold 1,665 shares of EXACT Sciences stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total transaction of $87,479.10. Following the sale, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Graham Peter Lidgard sold 45,770 shares of EXACT Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the sale, the insider now directly owns 237,820 shares in the company, valued at approximately $13,857,771.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 610,433 shares of company stock worth $34,341,306. Insiders own 4.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of EXACT Sciences by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after buying an additional 700,051 shares during the period. BlackRock Inc. raised its position in shares of EXACT Sciences by 1.2% during the 2nd quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after buying an additional 80,589 shares during the period. Fred Alger Management Inc. purchased a new stake in shares of EXACT Sciences during the 2nd quarter valued at approximately $84,177,000. Lord Abbett & CO. LLC raised its position in shares of EXACT Sciences by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after buying an additional 875,527 shares during the period. Finally, FMR LLC raised its position in shares of EXACT Sciences by 32.7% during the 2nd quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after buying an additional 571,796 shares during the period. 82.39% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “EXACT Sciences (EXAS) PT Set at $67.00 by Bank of America” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://transcriptdaily.com/2018/01/10/exact-sciences-exas-pt-set-at-67-00-by-bank-of-america.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply